Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and Flupentixol-Melitracen in Thyroid-Associated Ophthalmopathy
NCT06927375Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of flupentixol + melitracen in thyroid associated ophthalmopathy (TAO), anxiety disorder, sponsored by Shanghai Ninth People's Hospital. Started Dec 2024; status: recruiting.
02
Drugs
flupentixol + melitracen
03
Conditions
thyroid associated ophthalmopathy (TAO)anxiety disorder
Beyond the preview
Go deeper on NCT06927375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927375.